BIOGEN (BIIB) Company Report

Biocytogen (688796.SH; 02315.HK) became the first “H+A” dual-listing biotech to debut on the Shanghai Stock Exchange’s Sci-Tech Innovation Board, following its Hong Kong listing in September 2022.
The IPO price was RMB 26.68 per share, with a first-day opening price of RMB 58, representing a 117% increase; initial market capitalization was approximately RMB 25.9 billion.
The company specializes in innovative drug R&D, having developed the RenMice® full-human antibody platform with over 1,000 viable drug candidate sequences.
As of June 30, 2025, Biocytogen had signed 4,280 drug discovery collaborations, licensing and transfer agreements.

Dec 11, 2025, 9:25 AM

Press Release

Biocytogen completes STAR Market IPO with H+A dual-listing status

BIIB

Delisting/Listing Issues

Biocytogen wird als erstes globales innovatives Arzneimittelunternehmen H+A dual-notiert, nachdem es bereits im September 2022 in Hongkong gelistet war.
Der IPO-Preis lag bei 26,68 RMB pro Aktie, der Eröffnungskurs betrug 58 RMB, was einer Steigerung von 117 % gegenüber dem Ausgabepreis entspricht.
Auf Basis des Eröffnungskurses übersteigt die Marktkapitalisierung 25,9 Mrd. RMB.
Die proprietären RenMice®-Plattformen bieten über 1 Mio. menschliche Antikörpersequenzen für 1.000+ Targets sowie 4.390 gebrauchsfertige humanisierte Mausmodelle.
Die Emissionserlöse sollen in die globale Expansion, die Kommerzialisierung der Plattformen und strategischen Kapitaleinsatz fließen.

Dec 10, 2025, 4:50 PM

Press Release

Biocytogen completes STAR Market IPO

BIIB

Delisting/Listing Issues

Biocytogen priced its STAR Market IPO at 26.68 RMB per share, opening at 58 RMB (+117 %), giving it a market cap of over 25.9 billion RMB
Achieves dual “H+A” listing after its September 2022 Hong Kong IPO, becoming the first global innovator in this model
Proprietary RenMice® platforms span >1 000 drug targets and >1 million human antibody sequences, supporting >280 partnerships and >10 licensed clinical/preclinical programs
Positions the company to accelerate global expansion, platform commercialization, and strategic capital deployment leveraging its dual-listing structure

Dec 10, 2025, 4:43 PM

Press Release

Biocytogen completes STAR Market IPO, becomes first H+A global pharma innovator

BIIB

Delisting/Listing Issues

Biocytogen Pharmaceuticals successfully listed on the STAR Market of the Shanghai Stock Exchange, following its Hong Kong listing in September 2022.
The company is now the first "H+A" dual-listed global pharmaceutical innovator, combining listings in Shanghai and Hong Kong.
The IPO was priced at 26.68 RMB per share, with an opening price of 58 RMB, a 117% increase over the offering price.
This milestone advances Biocytogen’s ambition to become a global leader in innovative drug development.

Dec 10, 2025, 4:39 PM

Press Release

Biocytogen lists on Shanghai STAR Market in H+A dual IPO

BIIB

Delisting/Listing Issues

Biocytogen (688796.SH) successfully made its A-share debut on the Shanghai STAR Market as the first global new drug “H+A” dual-platform IPO, issuing at ¥26.68 per share and opening at ¥58 (+117%), with a market capitalization of ¥25.9 billion.
The company’s dual-engine R&D system combines its full-human antibody RenMice® library and humanized mouse platform, supporting over 1,000 lead candidates and a “1,000 mice, 10,000 antibodies” development program to accelerate novel biologics.
To date, Biocytogen has entered 280 drug collaboration, licensing, and partnering agreements and operates R&D and operational centers in China, the US, and Germany to drive global biotech partnerships.

Dec 10, 2025, 8:20 AM

Press Release

Biocytogen completes STAR Market IPO

BIIB

Delisting/Listing Issues

Biocytogen completed its IPO on the Shanghai STAR Market, becoming the first “H+A” global drug innovator dual-listed in Hong Kong and Shanghai.
The IPO was priced at 26.68 RMB per share, opened at 58 RMB (a 117% increase) and gave a market capitalization exceeding 25.9 billion RMB.
Its proprietary RenMice® platforms leverage a library of over one million antibody sequences across more than 1,000 druggable targets, supporting 40+ PCC-to-IND assets and 280+ discovery partnerships.
The listing is expected to drive global expansion, platform commercialization, and strategic capital deployment by leveraging its H+A dual-listing structure.

Dec 10, 2025, 2:50 AM

Press Release

Biogen highlights immunology pipeline at Piper Sandler Healthcare Conference

BIIB

Biogen’s CD38-directed antibody felzartamab showed in a 22-patient phase 2 study for late antibody-mediated rejection (AMR) in kidney transplant recipients that two-thirds of treated patients achieved zero microvascular inflammation at six months, with ~80% reversal; a phase 3 trial is underway with 12-month readout expected in 2027.
In IgA nephropathy, felzartamab’s nine-dose regimen demonstrated durable off-treatment reductions in proteinuria and total IgA out to two years, supporting a pivotal phase 3 program.
For primary membranous nephropathy, Biogen plans to target both high-risk PLA2R-positive patients and the 30–50% who relapse or don’t respond to anti-CD20 therapy by depleting CD38-expressing plasma cells.
Upcoming development includes a phase 1b lupus nephritis study (n=20), a phase 2 study in DSA-negative AMR, and additional proof-of-concept trials in other autoantibody-driven diseases with felzartamab.
Biogen’s broader lupus franchise features litifilamab (anti-BDCA2) with positive phase 2 SLE data and a CLE “Amethyst” study, plus dapirolizumab pegol (anti-CD40L) following one positive phase 3, with further phase 3 readouts due next year.

Dec 3, 2025, 4:30 PM

Transcript

Biogen highlights felzartamab renal and immunology pipeline at Piper Sandler conference

BIIB

Biogen’s felzartamab, a CD38-directed plasma cell therapy for antibody-mediated renal diseases, achieved ~80% reversal of microvascular inflammation at six months in a 22-patient Phase 2 study of late antibody-mediated rejection (AMR) vs. placebo.
The ongoing Phase 3 AMR trial (one-year duration) features a six-month crossover of placebo to felzartamab and maintenance dosing for active-arm patients, with top-line data expected in 2027.
In IgA nephropathy, a five-month felzartamab regimen yielded durable off-treatment reductions in proteinuria and total IgA for up to two years, potentially eliminating the need for continuous dosing.
Biogen will initiate additional felzartamab studies in DSA-negative AMR, lupus nephritis (Phase 1b), and other autoantibody-driven diseases, broadening its immunology development portfolio.

Dec 3, 2025, 4:30 PM

Transcript

Biogen presents LEQEMBI pharmacological effect data at CTAD 2025

BIIB

In a Phase III Clarity AD CSF sub-cohort (n=410), total CSF Aβ protofibril (PF) levels increased by 19% (placebo) vs 59% (lecanemab) at 12 months and 29% vs 45% at 18 months, with the 12-month difference reaching statistical significance (p=0.0126).
Data confirm target engagement of lecanemab: binding to PF and mobilization from brain parenchyma into CSF, indicating its pharmacodynamic effect in AD patients.
Lecanemab abolished the correlation between CSF PF changes and neurodegeneration biomarkers (total tau, neurogranin) seen in placebo, suggesting reduced PF-driven neurotoxicity.
Reinforces LEQEMBI as the only Alzheimer’s therapy targeting both protofibrils and amyloid plaques, potentially slowing downstream tau tangle accumulation on PET imaging.

Dec 2, 2025, 9:40 PM

Press Release

Biogen outlines pipeline and commercial strategy at Evercore HealthCONx

BIIB

Product Launch

New Projects/Investments

Biogen completed its Fit for Growth program under CEO Chris Viehbacher, delivering $1 billion in gross savings and $800 million in net savings to date.
The company has expanded from a single MS franchise to four franchises with 10 Phase III or Phase III–ready programs, including assets for tau, lupus, Parkinson’s and preclinical Alzheimer’s.
LEQEMBI’s IV maintenance is priced at 50% of the IV induction WAC, and the new IQLIK subcutaneous formulation will carry a 30% price reduction versus IV induction (two weekly injections).
The Zuranolone (ZURZUVAE) 14-day oral postpartum depression therapy is growing quarter-over-quarter after pivoting commercialization from psychiatrists to OB-GYNs and refining the “mental minute” engagement.
Felzartamab, acquired via HiBio, will launch sequentially in transplant antibody-mediated rejection (~11,000 patients), followed by MVI (4,000–5,000 patients) and IgAN, establishing a multi-indication nephrology franchise.

Dec 2, 2025, 5:55 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for BIOGEN.

Q3 2025

Oct 30, 2025

→

Q2 2025

Jul 31, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Christopher Viehbacher say about margins?What are BIOGEN's strategic priorities?How is BIOGEN positioned vs competitors?How did BIOGEN do last quarter?

BIOGEN (BIIB)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Christopher Viehbacher

Nicole Murphy

Priya Singhal

Robin Kramer

Sean Godbout

Susan Alexander

Board Members

Caroline Dorsa

Eric Rowinsky

Jesus Mantas

Lloyd Minor

Maria Freire

Mene Pangalos

Monish Patolawala

Stephen Sherwin

Susan Langer

William Hawkins

Analyst Coverage

Brian Abrahams

Michael Yee

Salveen Richter

Paul Matteis

Philip Nadeau

Umer Raffat

Evan Seigerman

Jay Olson

Christopher Schott

David Amsellem

Eric Schmidt

Marc Goodman

Terence Flynn

Geoffrey Meacham

Michael DiFiore

Miles Minter

Myles Minter

Tim Anderson

Timothy Anderson

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Ask Fintool AI Agent